JP Morgan Chase’s Artiva Biotherapeutics ARTV Stock Holding History

JP Morgan Chase’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.1K	Buy	4,191 +3,968	+1,779%	+$36.1K	﹤0.01%	6507
2026 Q1	$1.22K	Buy	223 +36	+19%	+$178	﹤0.01%	7098
2025 Q4	$802	Sell	187 -3,815	-95%	-$14.4K	﹤0.01%	7041
2025 Q3	$11.5K	Buy	4,002 +3,137	+363%	+$8.39K	﹤0.01%	6604
2025 Q2	$1.31K	Sell	865 -17,018	-95%	-$35.7K	﹤0.01%	6596
2025 Q1	$53.6K	Sell	17,883 -19,736	-52%	-$107K	﹤0.01%	5856
2024 Q4	$379K	Buy	37,619 +26,893	+251%	+$323K	﹤0.01%	5180
2024 Q3	$166K	Buy	+10,726	New	+$124K	﹤0.01%	5493

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

JP Morgan Chase's ARTV Position: Q2 2026 in Review

JP Morgan Chase increased its Artiva Biotherapeutics (ARTV) stake by 1,779% in Q2 2026, buying an estimated $36.1K and bringing the position to 4,191 shares worth $40.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6507.

JP Morgan Chase first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $379K in Q4 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

JP Morgan Chase held 4,191 shares of Artiva Biotherapeutics worth $40.1K as of Q2 2026.
JP Morgan Chase bought 3,968 Artiva Biotherapeutics shares in Q2 2026, an estimated $36.1K.
Artiva Biotherapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6507 holding.
JP Morgan Chase first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
JP Morgan Chase's Artiva Biotherapeutics position peaked at $379K in Q4 2024.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.